Skip to main content
Advertisement
Live broadcast

Scientists have identified a sign of late-stage chronic traumatic encephalopathy

JAMA: chronic traumatic encephalopathy is associated with accumulation of tau protein
0
Photo: IZVESTIA/Sergey Lantyukhov
Озвучить текст
Select important
On
Off

Chronic traumatic encephalopathy (CTE), a degenerative brain disease associated with repeated blows to the head, can today be reliably confirmed only after a person's death. However, researchers from the University of Washington School of Medicine found a protein fragment in the blood, the level of which increases in the late stages of the disease. The discovery may be a step towards creating a method for diagnosing CTE during life. How scientists have identified a new biomarker and why the analysis cannot yet be used in clinical practice is described in the Izvestia article.

Alzheimer's disease and CTE are associated with the accumulation of tau protein

The study is published in the journal JAMA Network. Scientists from Washington University School of Medicine in St. Louis have studied the protein fragment eMTBR-tau243, which was previously associated with the accumulation of tau protein in the brains of people with Alzheimer's disease.

Tau protein normally helps maintain the internal structure of nerve cells. However, in some neurodegenerative diseases, it forms toxic accumulations. There are two main forms of this protein: in some diseases, only one of them accumulates, whereas in Alzheimer's and CTE diseases, both accumulate.

Previously, researchers found that the concentration of the eMTBR-tau243 fragment in the blood reflects the accumulation of tau protein accumulations in the brains of patients with Alzheimer's disease. Now scientists have decided to check whether this biomarker is unique to her or whether it may indicate other diseases associated with the pathological accumulation of tau protein.

Kanta Hori, researcher and professor of Neurology and the University of Washington Medical Center and co-author of the study

Many pharmaceutical companies are developing treatments that can potentially help with CTE, but we do not have biomarkers that can detect the disease and quickly assess whether the treatment is working. We potentially open up a new opportunity for the diagnosis and treatment of CTE in living patients.

The connection between the protein fragment and CTE was discovered by chance

Together with colleagues from the University of California, San Francisco, the scientists studied samples from more than 80 people with brain diseases confirmed after death, as well as healthy volunteers. As expected, the level of eMTBR-tau243 was very high in people with Alzheimer's disease and low in neurodegenerative diseases characterized by the accumulation of only one form of tau protein.

However, one sample attracted the special attention of researchers. The person showed no signs of Alzheimer's disease, but the concentration of the biomarker was unexpectedly high. When re-examining the results of the postmortem brain examination, the scientists found out that this patient had a late stage of CTE. After that, the team tested the blood samples of 11 more people, in whom the disease was also confirmed after death. The level of eMTBR-tau243 in them was higher than in healthy people, and increased with the severity of brain damage.

Chihiro Sato, associate professor of neurology at the University of Washington Medical Center and co-author of the study

Our study shows that the biomarker of Alzheimer's disease can be used for other tauopathies, including CTE.

A blood test revealed the late stages of the disease

A total of 229 people participated in the study. To measure the concentration of the protein fragment, the scientists used the method of mass spectrometry. The analysis made it possible to accurately distinguish people with advanced CTE from healthy participants. At the same time, he cannot reliably detect the early stages of the disease yet. In addition, the concentration of eMTBR-tau243 in CTE was significantly lower than in Alzheimer's disease.

The results indicate that the biomarker reflects the accumulation of tau protein accumulations characteristic of several diseases. Therefore, its increase does not necessarily indicate chronic traumatic encephalopathy. The researchers consider the discovered protein fragment as a potential tool for further study of CTE, including for determining the severity of the disease and monitoring changes in the brain.

Why can't the analysis be used to diagnose CTE yet?

The University of Washington has licensed the eMTBR-tau243 blood measurement technology to a company that has also developed a blood test to help diagnose Alzheimer's disease. However, the test has not yet been tested to detect chronic traumatic encephalopathy.

More extensive research will be needed to confirm the results. One of the main difficulties is that elevated levels of this protein fragment are also found in Alzheimer's disease, which often develops simultaneously with CTE. Therefore, one biomarker does not reliably distinguish between these two diseases.

Chihiro Sato

It will not be an independent biomarker. But if a person has a history of repeated head injuries, tests for Alzheimer's disease are negative, and this biomarker is detected, this may indicate CTE.

A new biomarker may help monitor people at risk.

If the results are confirmed in large-scale studies, the blood test will potentially allow monitoring people with an increased risk of CTE. These include former American football players, boxers, and combat veterans who may have been repeatedly hit in the head.

In addition, the biomarker can help to conduct clinical trials of drugs aimed at pathological accumulations of tau protein, and to evaluate their effect faster. Currently, it is possible to definitively confirm chronic traumatic encephalopathy only after a person's death by examining brain tissue.

Переведено сервисом «Яндекс Переводчик»

Live broadcast